TB-500, KPV, GHK-Cu, and AOD-9604 are not FDA-approved for human use in any form
The evidence base is almost entirely preclinical: rodent models consistently show accelerated tissue repair, gut healing, and neurological protection, but human RCT data remains largely absent
sponsored a 24-week, randomized, placebo-controlled obesity trial (N=536) testing oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, and 20 mg daily
Additional research has investigated the relationship between Thymosin Beta-4 and various signaling pathways, including the Akt/PI3K pathway and modulation of inflammatory mediators
Evaluation of heterotopic bone formation induced by squalane and bone morphogenetic protein composite